NCT03979274View on ClinicalTrials.gov

A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 6, 2019

Primary Completion Date

January 13, 2020

Study Completion Date

January 25, 2020

Conditions
Healthy
Interventions
DRUG

Reference Eutirox®

Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.

DRUG

Test Eutirox®

Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.

Trial Locations (1)

58249

Cecype, Fray Bernardino de Sahagún, Morelia - Michoacan

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03979274 - A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers | Biotech Hunter | Biotech Hunter